Arvinas Q1 cash $1.17B, licenses ARV-766 to Novartis for $150M upfront

ARVINAS, INC.

2024-Q1 EPS reported -$0.97 revenue$25,300,000

Q1 2024 revenue $25.3M, down from $32.5M YoY; R&D expenses $84.3M vs $95.3M YoY.
Cash, equivalents and marketable securities $1,174.8M as of March 31, down $91.7M from year-end.
Licensed ARV-766 to Novartis for $150M upfront, up to $1.01B in milestones plus royalties.
Top-line data for vepdegestrant Phase 3 VERITAC-2 trial on track for 2H 2024.
Phase 1 trial initiated for ARV-102 (LRRK2 degrader) in neurodegenerative diseases.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARVINAS, INC. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 7, 2024 , Arvinas, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a corporate update.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001655759-24-000056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.